Chitosan nanoparticles for combined drug delivery and magnetic hyperthermia: from preparation to in vitro studies
Resumen: Chitosan nanoparticles (CSNPs) ionically crosslinked with tripolyphosphate salts (TPP) were employed as nanocarriers in combined drug delivery and magnetic hyperthermia (MH) therapy. To that aim, three different ferrofluid concentrations and a constant 5-fluorouracil (5-FU) concentration were efficiently encapsulated to yield magnetic CSNPs with core-shell morphology. In vitro experiments using normal cells, fibroblasts (FHB) and cancer cells, human glioblastoma A-172, showed that CSNPs presented a dose-dependent cytotoxicity and that they were successfully uptaken into both cell lines. The application of a MH treatment in A-172 cells resulted in a cell viability of 67–75% whereas no significant reduction of cell viability was observed for FHB. However, the A-172 cells showed re-growth populations 4 h after the application of the MH treatment when CSNPs were loaded only with ferrofluid. Finally, a combined effect of MH and 5-FU release was observed with the application of a second MH treatment for CSNPs exhibiting a lower amount of released 5-FU. This result demonstrates the potential of CSNPs for the improvement of MH therapies.
Idioma: Inglés
DOI: 10.1016/j.carbpol.2016.09.084
Año: 2017
Publicado en: CARBOHYDRATE POLYMERS 157 (2017), 361-370 [34 p.]
ISSN: 0144-8617

Factor impacto JCR: 5.158 (2017)
Categ. JCR: CHEMISTRY, APPLIED rank: 2 / 71 = 0.028 (2017) - Q1 - T1
Categ. JCR: POLYMER SCIENCE rank: 7 / 87 = 0.08 (2017) - Q1 - T1
Categ. JCR: CHEMISTRY, ORGANIC rank: 6 / 57 = 0.105 (2017) - Q1 - T1

Factor impacto SCIMAGO: 1.428 - Materials Chemistry (Q1) - Polymers and Plastics (Q1) - Organic Chemistry (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/MAT2010-19326
Financiación: info:eu-repo/grantAgreement/ES/MINECO/MAT2011-24797
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Área Física Materia Condensada (Dpto. Física Materia Condensa.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.


Exportado de SIDERAL (2020-02-17-12:41:58)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2019-05-08, última modificación el 2020-02-17


Postprint:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)